• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Pharmacological Treatment in Diabetes Mellitus Type 1 - Insulin and What Else?1型糖尿病的药物治疗——胰岛素及其他?
Int J Endocrinol Metab. 2017 Nov 20;16(1):e13008. doi: 10.5812/ijem.13008. eCollection 2018 Jan.
2
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.GLP-1 受体激动剂和二肽基肽酶-4 抑制剂作为二甲双胍的附加疗法在 2 型糖尿病患者中的血糖疗效:综述和荟萃分析。
Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24.
3
Non-insulin pharmacological therapies for treating type 1 diabetes.非胰岛素类药物治疗 1 型糖尿病。
Expert Opin Pharmacother. 2018 Jun;19(9):947-960. doi: 10.1080/14656566.2018.1483339.
4
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.胰高血糖素样肽-1 受体激动剂和二肽基肽酶-4 抑制剂的心血管作用和临床结局。
Circulation. 2017 Aug 29;136(9):849-870. doi: 10.1161/CIRCULATIONAHA.117.028136.
5
Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.二肽基肽酶-4抑制剂与二甲双胍联合治疗2型糖尿病:理论依据与证据
Diabetes Obes Metab. 2014 Feb;16(2):111-7. doi: 10.1111/dom.12128. Epub 2013 Jun 3.
6
Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.二甲双胍加磺脲类药物治疗失败后2型糖尿病治疗的网状Meta分析
Curr Med Res Opin. 2016 May;32(5):807-16. doi: 10.1185/03007995.2015.1135110. Epub 2016 Feb 29.
7
Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.二甲双胍对二肽基肽酶-IV活性的抑制作用增强了胰高血糖素样肽-1的抗糖尿病作用。
Eur J Pharmacol. 2006 Oct 10;547(1-3):192-9. doi: 10.1016/j.ejphar.2006.07.043. Epub 2006 Jul 27.
8
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.SGLT2(钠-葡萄糖共转运蛋白 2)抑制剂和 GLP-1(胰高血糖素样肽-1)受体激动剂如何降低心血管结局?:已完成和正在进行的机制试验。
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):506-522. doi: 10.1161/ATVBAHA.119.311904. Epub 2020 Jan 30.
9
Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis.使用两种不同的胰腺β细胞功能生物标志物比较二肽基肽酶-4 抑制剂与其他类别的降糖药物:一项荟萃分析。
PLoS One. 2020 Jul 24;15(7):e0236603. doi: 10.1371/journal.pone.0236603. eCollection 2020.
10
Complementing insulin therapy to achieve glycemic control.补充胰岛素治疗以实现血糖控制。
Adv Ther. 2013 Jun;30(6):557-76. doi: 10.1007/s12325-013-0039-y.

引用本文的文献

1
The effect of Iranian snake, venom on the blood glucose concentration and some biochemical parameters of experimental diabetic rats.伊朗蛇毒对实验性糖尿病大鼠血糖浓度及某些生化指标的影响。
Heliyon. 2024 Jan 10;10(2):e24436. doi: 10.1016/j.heliyon.2024.e24436. eCollection 2024 Jan 30.
2
Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis.达格列净和利拉鲁肽对糖尿病诱导大鼠心肌病的作用:氧化应激、炎症和细胞凋亡的影响。
Front Endocrinol (Lausanne). 2022 Mar 18;13:862394. doi: 10.3389/fendo.2022.862394. eCollection 2022.
3
Therapeutic potential of mesenchymal stem cells in treating both types of diabetes mellitus and associated diseases.间充质干细胞在治疗两种类型糖尿病及相关疾病中的治疗潜力。
J Diabetes Metab Disord. 2020 Oct 17;19(2):1979-1993. doi: 10.1007/s40200-020-00647-5. eCollection 2020 Dec.
4
A free-energy landscape for the glucagon-like peptide 1 receptor GLP1R.胰高血糖素样肽 1 受体 GLP1R 的自由能景观。
Proteins. 2020 Jan;88(1):127-134. doi: 10.1002/prot.25777. Epub 2019 Aug 2.
5
Obesity and diabetes-Not only a simple link between two epidemics.肥胖与糖尿病——不仅仅是两种流行病之间的简单关联。
Diabetes Metab Res Rev. 2018 Oct;34(7):e3042. doi: 10.1002/dmrr.3042. Epub 2018 Jul 17.

本文引用的文献

1
Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes.达格列净对胰岛素需求、葡萄糖排泄和β-羟丁酸水平的影响与 1 型糖尿病青少年的基线 HbA1c 无关。
Diabetes Obes Metab. 2017 Nov;19(11):1635-1639. doi: 10.1111/dom.12975. Epub 2017 Jun 22.
2
Use of Sitagliptin With Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes.使用西他列汀联合闭环技术降低1型糖尿病患者的餐后血糖
J Diabetes Sci Technol. 2017 May;11(3):602-610. doi: 10.1177/1932296817699847. Epub 2017 Mar 28.
3
Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes.胰高血糖素样肽-1受体激动剂疗法对1型糖尿病患者的心血管影响。
Diabetes Obes Metab. 2017 May;19(5):613-614. doi: 10.1111/dom.12883. Epub 2017 Mar 2.
4
Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice.二肽基肽酶-4抑制剂吉格列汀对链脲佐菌素诱导的1型糖尿病小鼠的肾脏保护作用
Diabetes Metab J. 2016 Jun;40(3):211-21. doi: 10.4093/dmj.2016.40.3.211. Epub 2016 Apr 21.
5
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.美国临床内分泌医师协会和美国内分泌学会关于钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂与糖尿病酮症酸中毒相关性的立场声明
Endocr Pract. 2016 Jun;22(6):753-62. doi: 10.4158/EP161292.PS. Epub 2016 Jun 1.
6
Treatment of diabetes in children.儿童糖尿病的治疗。
Exp Ther Med. 2016 Apr;11(4):1168-1172. doi: 10.3892/etm.2016.3039. Epub 2016 Jan 29.
7
Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials.病程对普兰林肽治疗1型糖尿病疗效的影响:三项临床试验的事后分析
Adv Ther. 2016 May;33(5):848-61. doi: 10.1007/s12325-016-0326-5. Epub 2016 Apr 12.
8
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.非胰岛素类药物治疗 1 型糖尿病高血糖。
Lancet Diabetes Endocrinol. 2016 Sep;4(9):766-780. doi: 10.1016/S2213-8587(16)00039-5. Epub 2016 Mar 9.
9
Amylin-mediated control of glycemia, energy balance, and cognition.胰淀素介导的血糖、能量平衡及认知调控。
Physiol Behav. 2016 Aug 1;162:130-40. doi: 10.1016/j.physbeh.2016.02.034. Epub 2016 Feb 27.
10
Metabolicsyndrome in youngpatients.年轻患者中的代谢综合征
Pediatr Endocrinol Diabetes Metab. 2015 Dec 15;21(1):32-6. doi: 10.18544/PEDM-21.01.0022.

1型糖尿病的药物治疗——胰岛素及其他?

Pharmacological Treatment in Diabetes Mellitus Type 1 - Insulin and What Else?

作者信息

Otto-Buczkowska Ewa, Jainta Natalia

机构信息

Medical Specialist Centre in Gliwice, Poland.

Medical University of Silesia in Katowice, Poland.

出版信息

Int J Endocrinol Metab. 2017 Nov 20;16(1):e13008. doi: 10.5812/ijem.13008. eCollection 2018 Jan.

DOI:10.5812/ijem.13008
PMID:29696037
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5903388/
Abstract

The basis of treatment in autoimmune diabetes is insulin therapy; however, many clinical cases have proven that this method does not solve all problems. Trials of causal treatment including blocking the autoimmune processes and insulin-producing cells transplants were carried out. Those methods require more research to be concerned as efficient and safe ways of treatment in type 1 diabetes. The use of non-insulin adjunct treatment is a new trend. It has been successfully used in laboratories as well as clinical trials. Metformin is the most widely used drug, together with sodium-glucose co-transporters 2 (SGLT2) inhibitors, amylin analogues, glucagon-like peptide 1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors. The results of administration of these medicaments give good outcomes in patients with diabetes mellitus type 1. Most likely, in the near future, they will progressively be used in both adult and adolescent patients with type 1 diabetes. Further multicenter, randomized studies are required to evaluate the efficacy of treatment and long term safety of these drugs.

摘要

自身免疫性糖尿病的治疗基础是胰岛素治疗;然而,许多临床病例证明这种方法并不能解决所有问题。开展了包括阻断自身免疫过程和胰岛移植在内的病因治疗试验。作为1型糖尿病高效且安全的治疗方法,这些方法还需要更多研究。使用非胰岛素辅助治疗是一种新趋势。它已在实验室以及临床试验中成功应用。二甲双胍是使用最广泛的药物,还有钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂、胰淀素类似物、胰高血糖素样肽1(GLP-1)受体激动剂和二肽基肽酶-4(DPP-4)抑制剂。这些药物的给药结果在1型糖尿病患者中取得了良好疗效。很可能在不久的将来,它们将逐渐用于成年和青少年1型糖尿病患者。需要进一步开展多中心、随机研究来评估这些药物的治疗效果和长期安全性。